Immunic Q3 net loss $21.2M; goodwill impairment ~$33M; cash $129M; IMU-935 psoriasis trial misses

IMMUNIC, INC.

2022-Q3 EPS reported -$2.16

Net loss $21.2M ($0.69/share) vs $19.3M ($0.76) in Q3 2021; R&D $16.5M, G&A $3.6M.
Cash $72.8M at Sept 30; plus $56.4M net from Oct private placement => runway into Q4 2024.
Expects goodwill impairment of ~$33M in Q4 2022 due to stock decline after IMU-935 psoriasis data.
IMU-935 psoriasis phase 1b: interim data showed no separation from placebo; high placebo rate; update Q1 2023.
IMU-856 phase 1 Parts A/B positive; Part C in celiac disease ongoing, data 2023; patent allowance received.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IMMUNIC, INC. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022 and providing a corporate update

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-22-001472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.